{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:45:21Z","timestamp":1759481121535,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan","doi-asserted-by":"crossref","award":["16H05844"],"award-info":[{"award-number":["16H05844"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Japan Initiative for Global Research Network on Infectious Diseases (J-GRID)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40256-017-0240-5","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T03:20:02Z","timestamp":1498620002000},"page":"93-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Effect of Endothelin Receptor Antagonists in Patients with Eisenmenger Syndrome: A Systematic Review"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-6341","authenticated-orcid":false,"given":"Abdelrahman","family":"Elshafay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-1744","authenticated-orcid":false,"given":"Duy Hieu","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3719-1117","authenticated-orcid":false,"given":"Mohamed M.","family":"AboElnas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4087-7264","authenticated-orcid":false,"given":"Hossam","family":"Idrees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2773-6443","authenticated-orcid":false,"given":"Hatem G.","family":"Metwali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2684-3041","authenticated-orcid":false,"given":"Nguyen Lam","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4681-2672","authenticated-orcid":false,"given":"Omar Ahmed","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-1777","authenticated-orcid":false,"given":"Kenji","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-9440","authenticated-orcid":false,"given":"Nguyen Tien","family":"Huy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"issue":"21","key":"240_CR1","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.jacc.2011.08.025","volume":"58","author":"D Linde van der","year":"2011","unstructured":"van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58(21):2241\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"240_CR2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijcard.2014.04.072","volume":"174","author":"A Riel Van","year":"2014","unstructured":"Van Riel A, Schuuring M, Van Hessen I, Zwinderman A, Cozijnsen L, Reichert C, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol. 2014;174(2):299\u2013305.","journal-title":"Int J Cardiol"},{"issue":"25","key":"240_CR3","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","volume":"62","author":"G Simonneau","year":"2013","unstructured":"Simonneau G, Gatzoulis M, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25):D34\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"240_CR4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jacc.2008.11.025","volume":"53","author":"M Beghetti","year":"2009","unstructured":"Beghetti M, Gali\u00e8 N. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53(9):733\u201340.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"240_CR5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/pcad.2002.127492","volume":"45","author":"E Berman","year":"2002","unstructured":"Berman E, Barst R. Eisenmenger\u2019s syndrome: current management. Progress in cardiovascular diseases. Prog Cardiovasc Dis. 2002;45(2):129\u201338.","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"240_CR6","first-page":"169","volume":"67","author":"D Frank","year":"2015","unstructured":"Frank D, Hanna B. Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics. Miner Pediatr. 2015;67(2):169.","journal-title":"Miner Pediatr"},{"issue":"18","key":"240_CR7","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/eurheartj\/ehv743","volume":"37","author":"G Diller","year":"2016","unstructured":"Diller G, K\u00f6rten M, Bauer U, Miera O, Tutarel O, Kaemmerer H, et al. Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects. Eur Heart J. 2016;37(18):1449\u201355.","journal-title":"Eur Heart J"},{"key":"240_CR8","doi-asserted-by":"crossref","unstructured":"Fukushima H. Update on medical treatment of patients with Eisenmenger syndrome. Int Heart J. 2015;56(Suppl:S4-7).","DOI":"10.1536\/ihj.14-347"},{"issue":"1","key":"240_CR9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1165\/ajrcmb.25.1.4331","volume":"25","author":"S Wort","year":"2001","unstructured":"Wort S, Woods M, Warner T, Evans T, Mitchell J. Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling. Am J Respir Cell Mol Biol. 2001;25(1):104\u201310.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"240_CR10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","volume":"358","author":"R Channick","year":"2001","unstructured":"Channick R, Simonneau G, Sitbon O, Robbins I, Frost A, Tapson V, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119\u201323.","journal-title":"Lancet"},{"issue":"1","key":"240_CR11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2004.08.025","volume":"98","author":"MA Gatzoulis","year":"2005","unstructured":"Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol. 2005;98(1):147\u201351.","journal-title":"Int J Cardiol"},{"issue":"5","key":"240_CR12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cardfail.2012.02.004","volume":"18","author":"MG Kaya","year":"2012","unstructured":"Kaya MG, Lam YY, Erer B, Ayhan S, Vatankulu MA, Nurkalem Z, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail. 2012;18(5):379\u201384.","journal-title":"J Card Fail"},{"key":"240_CR13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"L Rubin","year":"2002","unstructured":"Rubin L, Badesch D, Barst R, Galie N, Black C, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896\u2013903.","journal-title":"N Engl J Med"},{"issue":"339","key":"240_CR14","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"21","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman D, Tetzlaff J, Mulrow C, G\u00f8tzsche P, Ioannidis J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;21(339):b2700.","journal-title":"BMJ"},{"key":"240_CR15","unstructured":"Huy N, Elshafay A, Vuong N, Truong D, AboElnas M, Gamal H, et al. Safety and efficacy of endothelin receptor antagonist on cardiac function in patients with Eisenmenger syndrome a systematic review and meta-analysis of randomized clinical trials. PROSPERO 2016:CRD42016048731."},{"issue":"343","key":"240_CR16","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"18","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;18(343):d5928.","journal-title":"BMJ"},{"issue":"1","key":"240_CR17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","volume":"114","author":"N Gali\u00e8","year":"2006","unstructured":"Gali\u00e8 N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48\u201354.","journal-title":"Circulation"},{"issue":"1","key":"240_CR18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijcard.2007.04.078","volume":"127","author":"MA Gatzoulis","year":"2008","unstructured":"Gatzoulis MA, Beghetti M, Galie N, Granton J, Berger RM, Lauer A, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127(1):27\u201332.","journal-title":"Int J Cardiol"},{"issue":"3","key":"240_CR19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ijcard.2009.04.037","volume":"144","author":"RM Berger","year":"2010","unstructured":"Berger RM, Beghetti M, Galie N, Gatzoulis MA, Granton J, Lauer A, et al. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger\u2019s syndrome: a subgroup analysis. Int J Cardiol. 2010;144(3):373\u20138.","journal-title":"Int J Cardiol"},{"issue":"9","key":"240_CR20","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","volume":"31","author":"K Iversen","year":"2010","unstructured":"Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31(9):1124\u201331.","journal-title":"Eur Heart J"},{"issue":"5","key":"240_CR21","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.13-1864","volume":"145","author":"R Coeytaux","year":"2014","unstructured":"Coeytaux R, Schmit K, Kraft B, Kosinski A, Mingo A, Vann L, et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2014;145(5):1055\u201363.","journal-title":"Chest"},{"issue":"5","key":"240_CR22","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00408-016-9928-6","volume":"194","author":"M Kuntz","year":"2016","unstructured":"Kuntz M, Leiva-Juarez M, Luthra S. Systematic review of randomized controlled trials of endothelin receptor antagonists for pulmonary arterial hypertension. Lung. 2016;194(5):723\u201332.","journal-title":"Lung"},{"key":"240_CR23","doi-asserted-by":"crossref","unstructured":"Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2013 (2):CD004434.","DOI":"10.1002\/14651858.CD004434.pub5"},{"key":"240_CR24","doi-asserted-by":"crossref","unstructured":"Hascoet S, Fournier E, Ja\u00efs X, Le Gloan L, Dauphin C, Houeijeh A, et al. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: a French multicentre study. Arch Cardiovasc Dis. 2017.","DOI":"10.1016\/j.acvd.2017.01.006"},{"issue":"6","key":"240_CR25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/HCO.0b013e3283126954","volume":"23","author":"K Dimopoulos","year":"2008","unstructured":"Dimopoulos K, Giannakoulas G, Wort S, Gatzoulis M. Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Curr Opin Cardiol. 2008;23(6):545\u201354.","journal-title":"Curr Opin Cardiol"},{"key":"240_CR26","unstructured":"Kempny A, Hjortsh\u00f8j CS, Gu H, Li W, Opotowsky AR, Landzberg M, et al. Predictors of death in contemporary adult patients with Eisenmenger syndrome: a multicentre study. Circulation. 2016:CIRCULATIONAHA.116.023033."},{"issue":"10","key":"240_CR27","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/heart.89.10.1221","volume":"89","author":"SC Apostolopoulou","year":"2003","unstructured":"Apostolopoulou SC, Rammos S, Kyriakides ZS, Webb DJ, Johnston NR, Cokkinos DV, et al. Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease. Heart. 2003;89(10):1221\u20136.","journal-title":"Heart"},{"issue":"12","key":"240_CR28","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"L Rubin","year":"2002","unstructured":"Rubin L, Badesch D, Barst R, Galie N, Black C, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896\u2013903.","journal-title":"N Engl J Med"},{"issue":"11","key":"240_CR29","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/hrt.2004.051961","volume":"91","author":"SC Apostolopoulou","year":"2005","unstructured":"Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart. 2005;91(11):1447\u201352.","journal-title":"Heart"},{"issue":"4","key":"240_CR30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/157340310793566127","volume":"6","author":"E Oechslin","year":"2010","unstructured":"Oechslin E, Mebus S, Schulze-Neick I, Niwa K, Trindade P, Eicken A, et al. The adult patient with Eisenmenger syndrome: a medical update after Dana Point part III: specific management and surgical aspects. Curr Cardiol Rev. 2010;6(4):363\u201372.","journal-title":"Curr Cardiol Rev"},{"issue":"3","key":"240_CR31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.hfc.2012.04.002","volume":"8","author":"V Gupta","year":"2012","unstructured":"Gupta V, Tonelli A, Krasuski R. Congenital heart disease and pulmonary hypertension. Heart Fail Clin. 2012;8(3):427\u201345.","journal-title":"Heart Fail Clin"},{"issue":"3","key":"240_CR32","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijcard.2008.02.025","volume":"134","author":"MG Duffels","year":"2009","unstructured":"Duffels MG, Vis JC, van Loon RL, Berger RM, Hoendermis ES, van Dijk AP, et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option? Int J Cardiol. 2009;134(3):378\u201383.","journal-title":"Int J Cardiol"},{"issue":"5","key":"240_CR33","first-page":"165","volume":"14","author":"MGJ Duffels","year":"2006","unstructured":"Duffels MGJ, Berger RMF, Bresser P, de Bruin-Bon HACM, Hoendermis E, Bouma BJ, et al. Applicability of bosentan in Dutch patients with Eisenmenger syndrome preliminary results on safety and exercise capacity. Neth Heart J. 2006;14(5):165\u201370.","journal-title":"Neth Heart J"},{"issue":"10","key":"240_CR34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.hlc.2010.07.005","volume":"19","author":"FD Kermeen","year":"2010","unstructured":"Kermeen FD, Franks C, O\u2019Brien K, Seale H, Hall K, McNeil K, et al. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21. Heart Lung Circ. 2010;19(10):595\u2013600.","journal-title":"Heart Lung Circ"},{"issue":"3","key":"240_CR35","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijcard.2010.10.051","volume":"155","author":"M D\u2019Alto","year":"2012","unstructured":"D\u2019Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, et al. Bosentan\u2013Sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012;155(3):378\u201382.","journal-title":"Int J Cardiol"},{"issue":"3","key":"240_CR36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/heartjnl-2013-304895","volume":"100","author":"J Douwes","year":"2014","unstructured":"Douwes J, Roofthooft M, Van Loon R, Ploegstra M, Bartelds B, Hillege H, et al. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre. Heart. 2014;100(3):224\u201330.","journal-title":"Heart"},{"key":"240_CR37","doi-asserted-by":"crossref","unstructured":"Amedro P, Basquin A, Gressin V, Clerson P, Jais X, Thambo J-B, et al. Health-related quality of life of patients with pulmonary arterial hypertension associated with CHD: the multicentre cross-sectional ACHILLE study. Cardiology in the Young. 2016:1\u201310.","DOI":"10.1017\/S1047951116000056"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-017-0240-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0240-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0240-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T04:30:04Z","timestamp":1569558604000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-017-0240-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["240"],"URL":"https:\/\/doi.org\/10.1007\/s40256-017-0240-5","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2017,6,28]]}}}